Please see Full Prescribing Information: This video is intended for healthcare professionals only.
Dr. Marin Xavier and Ashley Harder, registered nurse (RN) review CALQUENCE® (acalabrutinib) efficacy and safety data, followed by nursing-focused aspects of CALQUENCE patient management, including dosing, patient education, and adverse event management.
Select Safety Information
CALQUENCE is indicated for the treatment of adults with previously treated mantle cell lymphoma (MCL). This indication is approved under accelerated approval; continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions (≥ 20%) of any grade in patients with relapsed or refractory MCL were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.
0 Comments